LL-37 via EGFR transactivation to promote high glucose-attenuated epithelial wound healing in organ-cultured corneas.
Yin. Jia J; Yu. Fu-Shin X FS
Key Findings
- LL-37 triggers release of HB‑EGF and activates EGFR in a dose‑dependent way
- LL-37 improves scratch‑wound closure in cultured corneal cells and partially reverses high‑glucose‑induced healing delays
- The healing benefit depends on EGFR and PI3K signaling and works in both human cells and porcine corneas
Practical Outcomes
- Topical LL-37 or similar peptide formulations could become a strategy to support corneal repair in diabetics, but human safety and dosing studies are still needed. Biohackers might watch for emerging eye‑drop products or DIY formulations, keeping an eye on concentration limits and potential irritation.
Summary
LL-37, a natural antimicrobial peptide, can boost eye surface healing by turning on the EGFR pathway, even when blood sugar is high. In lab-grown corneal cells and pig eyes, adding LL-37 helped close wounds faster and rescued the slowdown caused by high glucose, suggesting it might be useful for diabetic eye problems.
Abstract
Purpose. Patients with diabetes are at higher risk for delayed corneal reepithelialization and infection. Previous studies indicated that high glucose (HG) impairs epidermal growth factor receptor (EGFR) signaling and attenuates ex vivo corneal epithelial wound healing. The authors investigated the effects of antimicrobial peptide LL-37 on HG-attenuated corneal epithelial EGFR signaling and wound closure. Methods. Human corneal epithelial cells (HCECs) were stimulated with LL-37. Heparin-binding EGF-like growth factor (HB-EGF) shedding was assessed by measuring the release of alkaline phosphatase (AP) in a stable HCEC line expressing HB-EGF-AP. Activation of EGFR, phosphoinositide 3-kinase (PI3K), and extracellular signal-regulated kinases 1/2 (ERK1/2) was determined by Western blot analysis. Corneal epithelial wound closure was assessed in cultured HCECs and porcine corneas. LL-37 expression was determined by immune dot blot. Results. LL-37 induced HB-EGF-AP release and EGFR activation in a dose-dependent manner. LL-37 prolonged EGFR signaling in response to wounding. LL-37 enhanced the closure of a scratch wound in cultured HCECs and partially rescued HG-attenuated wound healing in an EGFR- and a PI3K-dependent manner and restored HG-impaired EGFR signaling in cultured porcine corneas. HG attenuated wounding-induced LL-37 expression in cultured HCECs. Conclusions. LL-37 is a tonic factor promoting EGFR signaling and enhancing epithelial wound healing in normal and high glucose conditions. With both antimicrobial and regenerative capabilities, LL-37 may be a potential therapeutic for diabetic keratopathy.
Study Information
pubmed
2009
2009-09-24T00:00:00.000Z
10.1167/iovs.09-3904
72
66